Publisher
Springer Science and Business Media LLC
Reference67 articles.
1. Karyopharm Therapeutics Inc. XPOVIO™ (selinexor) tablets, for oral use: US prescribing information; 2019.
https://www.fda.gov
. Accessed 2 Aug 2019.
2. Gounder MM, Zer A, Tap WD, et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol. 2016;34(26):3166–74.
3. Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142–50.
4. Gandhi UH, Senapedis W, Baloglu E, et al. Clinical implications of targeting XPO1-mediated muclear export in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(5):335–45.
5. Karyopharm Therapeutics. Karyopharm announces FDA approval of XPOVIO™ (selinexor) for the treatment of patients with relapsed or refractory multiple myeloma [media release]. 3 Jul 2019.
http://www.karyopharm.com
.
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献